|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, January 28, 2017 ) ReportsWeb.com has announced the addition of the “Hypertriglyceridemia - Pipeline Review, H2 2016” The report outlines the evolution of enterprise content management, and identifies and assesses the best performing vendors in the market.
Summary
Pharmaceutical and Healthcare latest pipeline guide Hypertriglyceridemia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hypertriglyceridemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hypertriglyceridemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypertriglyceridemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 9, 1, 2, 11 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.
Hypertriglyceridemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/hypertriglyceridemia-pipeline-review-h2-2016
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hypertriglyceridemia (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Hypertriglyceridemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hypertriglyceridemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hypertriglyceridemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hypertriglyceridemia (Metabolic Disorders)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hypertriglyceridemia (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hypertriglyceridemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001530744/sample
Few Points from Table of Content:
List of Tables 6
List of Figures 7
Introduction 8
Publisher Report Coverage 8
Hypertriglyceridemia Overview 9
Therapeutics Development 10
Pipeline Products for Hypertriglyceridemia - Overview 10
Pipeline Products for Hypertriglyceridemia - Comparative Analysis 11
Hypertriglyceridemia - Therapeutics under Development by Companies 12
Hypertriglyceridemia - Therapeutics under Investigation by Universities/Institutes 14
Hypertriglyceridemia - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Hypertriglyceridemia - Products under Development by Companies 18
Hypertriglyceridemia - Products under Investigation by Universities/Institutes 19
Hypertriglyceridemia - Companies Involved in Therapeutics Development 20
Acasti Pharma Inc 20
Akcea Therapeutics Inc 21
Allergan Plc 22
Alnylam Pharmaceuticals Inc 23
Arisaph Pharmaceuticals Inc 24
AstraZeneca Plc 25
BASF SE 26
Cardax Inc 27
Catabasis Pharmaceuticals Inc 28
Celon Pharma SA 29
CymaBay Therapeutics Inc 30
Gemphire Therapeutics Inc 31
Jeil Pharmaceutical Co Ltd 32
Kyorin Pharmaceutical Co Ltd 33
LipimetiX Development Inc 34
Matinas BioPharma Holdings Inc 35
Sancilio & Company Inc 36
Zydus Cadila Healthcare Ltd 37
Hypertriglyceridemia - Therapeutics Assessment 38
Assessment by Monotherapy Products 38
Assessment by Target 39
Assessment by Mechanism of Action 41
Assessment by Route of Administration 43
Assessment by Molecule Type 45
Drug Profiles 47
AEM-28 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
AEM-2814 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
ALN-AC3 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
ALN-ANG - Drug Profile 51
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
